Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

5.1K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

467
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
467
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

477
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
477

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Loss of WNT2B Increases Tumor Burden and Malignant Features in Colorectal Cancer.

Cancer communications (London, England)·2026
Same author

SORBS2 regulates diastolic function through cytoskeletal networks and calcium handling.

Communications biology·2026
Same author

Placental Evidence of Intrauterine Stress: Mechanisms, Timing, and Links to Perinatal Brain Injury.

Journal of clinical medicine·2026
Same author

Drug Induced Liver Injury in Children: Practical Considerations for Pathologists.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same author

Childhood-Onset Desmin-Related Cardiomyopathy: Comprehensive Clinical, Histopathological, Immunohistochemical, Ultrastructural, and Molecular Characterization.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same author

Chemerin knockout reveals sex difference in the role of chemerin in blood pressure and vascular remodeling.

American journal of physiology. Heart and circulatory physiology·2026
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 16, 2025

Pull-down of Calmodulin-binding Proteins
07:51

Pull-down of Calmodulin-binding Proteins

Published on: January 23, 2012

25.3K

カルモジュリノパシーに対するアンチセンスオリゴヌクレオチド療法

Raul H Bortolin1, Farina Nawar1, Chaehyoung Park1

  • 1Department of Cardiology (R.H.B., F.N., C.P., M.A.T., M.P., M.E.S., P.W., J.C., F.L., C.L., P.B., E.M.K., D.Y., N.P., T.S., Q.M., D.J.A., V.J.B., W.T.P.).

Circulation
|August 19, 2024
PubMed
まとめ
この要約は機械生成です。

特定のカルモジュリン遺伝子を標的にするアンチセンスオリゴヌクレオチド (ASO) は,遺伝性不律症候群の治療に有望である. このアプローチは,カルモジュリン濃度を損なうことなく,モデルにおける心臓機能を効果的に正常化させました.

キーワード:
アンチセンス オリゴヌクレオチドカルシウム長いQTシンドローム精密医療短心,心室性

さらに関連する動画

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.6K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.4K

関連する実験動画

Last Updated: Jun 16, 2025

Pull-down of Calmodulin-binding Proteins
07:51

Pull-down of Calmodulin-binding Proteins

Published on: January 23, 2012

25.3K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.6K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.4K

科学分野:

  • 心血管遺伝学
  • 分子心臓科
  • 遺伝医学

背景:

  • カルモジュリノパシーは珍しい遺伝性心拍不全症候群です.
  • これらの条件は,カルモジュリン (CaM) タンパク質をコードするCALM1,CALM2,またはCALM3遺伝子の支配的な異性体の変異から生じる.
  • これらの遺伝子の間の CaM タンパク質の同一性は治療上の課題となっています.

研究 の 目的:

  • 影響を受けたカルモジュリン遺伝子の反意味オリゴヌクレオチド (ASO) 媒介による枯渇が疾患の症状を改善する可能性があるという仮説を検証する.
  • 他のカルモジュリン遺伝子が,標的の枯渇時にCaMのレベルと機能を維持できるかどうかを決定する.
  • カルモジュリノパシーに対する潜在的な治療戦略としてASOを探求する.

主な方法:

  • ヒト誘発性多能幹細胞由来心筋細胞 (hiPSC-CMs) とCALM1の病原性多様体を持つマウスモデルを使用した.
  • hiPSC- CMのCALM1とネズミのCALM1を標的としたASOを投与した.
  • アクションポテンシャル持続時間,再極化,CaMタンパク質レベル,トランスクリプトレベル,および心臓の電気および収縮機能に対する評価効果.

主要な成果:

  • 人間のCALM1変異のhiPSC- CMは,先天的な長いQT症候群をモデル化して,長時間作用の可能性を示した.
  • CALM1を消耗させるASOは,影響を受けたhiPSC- CMにおいて,CaMタンパク質濃度を変えることなく,再極化を正常化させた.
  • ネズミのCalm1を標的にしたASOは,Calm1のトランスクリプトを枯渇させ,マウスにおける薬剤誘発性心房短縮症を緩和し,心臓機能を損なわなかった.

結論:

  • カルモジュリノパシーにおけるASO媒介治療の概念実証
  • カルモジュリン遺伝子を標的にするASOは潜在的に効果的な治療法です.
  • この治療戦略は安全であり,全体的なCaMレベルと心臓の機能を保ちます.